Gyre Therapeutics, Inc. GYRE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $117.05M+0.4% | $116.59M+8.7% | $107.27M+5.0% | $102.19M+1.5% | $100.64M-4.8% | ||
| $5.75M+6.1% | $5.42M+11.7% | $4.85M+16.0% | $4.18M+10.0% | $3.8M-2.2% | ||
| $111.3M+0.1% | $111.17M+8.6% | $102.42M+4.5% | $98.01M+1.2% | $96.84M-4.9% | ||
| 95.1%-0.3pp | 95.4%-0.1pp | 95.5%-0.4pp | 95.9%-0.3pp | 96.2%-0.1pp | ||
| $17.34M+26.6% | $13.7M+8.8% | $12.6M-3.2% | $13.01M+0.5% | $12.94M+7.6% | ||
| $68.47M+5.1% | $65.18M+12.0% | $58.22M+2.9% | $56.59M+1.4% | $55.81M-3.0% | ||
| $23.07M+10.9% | $20.8M+6.3% | $19.57M+2.6% | $19.07M+8.0% | $17.67M+9.7% | ||
| $117.19M+11.5% | $105.1M+10.4% | $95.23M+2.6% | $92.85M+2.8% | $90.28M+0.8% | ||
| -$141K-101% | $11.49M-4.5% | $12.03M+28.8% | $9.34M-9.9% | $10.37M-35.9% | ||
| -0.1%-10.0pp | 9.9%-1.4pp | 11.2%+2.1pp | 9.1%-1.2pp | 10.3%-5.0pp | ||
| -$1.58M-5.2% | -$1.51M-59.3% | -$945K+45.9% | -$1.75M-4.4% | -$1.67M-0.9% | ||
| $630K-95.7% | $14.5M-5.1% | $15.27M+32.0% | $11.58M-24.7% | $15.37M-33.8% | ||
| $4.28M-6.1% | $4.56M+31.7% | $3.46M+21.8% | $2.84M-22.7% | $3.68M-30.9% | ||
| —— | —— | $6.75M+58.3% | $4.26M-42.0% | $7.35M-39.7% | ||
| —— | —— | $0.03+200% | $0.01-50.0% | $0.02-60.0% | ||
| $2.48M-82.3% | $13.97M-2.5% | $14.32M+25.4% | $11.42M-5.1% | $12.03M-32.1% | ||
| 2.1%-9.9pp | 12%-1.4pp | 13.4%+2.2pp | 11.2%-0.8pp | 12%-4.8pp | ||
| -$141K-101% | $11.49M-4.5% | $12.03M+28.8% | $9.34M-9.9% | $10.37M-35.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $117.0M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $1.9M over the trailing twelve months, a 6.3% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 95.1% and operating margin is -0.1%, with a 6.3% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.07.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
